These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39122009)

  • 1. SOX2 represses c-MYC transcription by altering the co-activator landscape of the c-MYC super-enhancer and promoter regions.
    Ormsbee Golden BD; Gonzalez DV; Yochum GS; Coulter DW; Rizzino A
    J Biol Chem; 2024 Sep; 300(9):107642. PubMed ID: 39122009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
    Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
    Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancer identification in mouse embryonic stem cells using integrative modeling of chromatin and genomic features.
    Chen CY; Morris Q; Mitchell JA
    BMC Genomics; 2012 Apr; 13():152. PubMed ID: 22537144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
    Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
    Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression.
    Jiang Y; Jiang YY; Xie JJ; Mayakonda A; Hazawa M; Chen L; Xiao JF; Li CQ; Huang ML; Ding LW; Sun QY; Xu L; Kanojia D; Jeitany M; Deng JW; Liao LD; Soukiasian HJ; Berman BP; Hao JJ; Xu LY; Li EM; Wang MR; Bi XG; Lin DC; Koeffler HP
    Nat Commun; 2018 Sep; 9(1):3619. PubMed ID: 30190462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supercharging BRD4 with NUT in carcinoma.
    Eagen KP; French CA
    Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer.
    Liu Y; Wu Z; Zhou J; Ramadurai DKA; Mortenson KL; Aguilera-Jimenez E; Yan Y; Yang X; Taylor AM; Varley KE; Gertz J; Choi PS; Cherniack AD; Chen X; Bass AJ; Bailey SD; Zhang X
    Nat Commun; 2021 Dec; 12(1):7139. PubMed ID: 34880227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor.
    Wang C; Mayer JA; Mazumdar A; Fertuck K; Kim H; Brown M; Brown PH
    Mol Endocrinol; 2011 Sep; 25(9):1527-38. PubMed ID: 21835891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The co-activator p300 associates physically with and can mediate the action of the distal enhancer of the FGF-4 gene.
    Nowling T; Bernadt C; Johnson L; Desler M; Rizzino A
    J Biol Chem; 2003 Apr; 278(16):13696-705. PubMed ID: 12488456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hold the MYCrophone: MYC Invades Enhancers to Control Cancer-Type Gene Programs.
    MacPherson-Hawthorne K; Sears RC
    Cancer Res; 2024 Jul; 84(14):2227-2228. PubMed ID: 38695859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch.
    Jakobsen ST; Jensen RAM; Madsen MS; Ravnsborg T; Vaagenso CS; Siersbæk MS; Einarsson H; Andersson R; Jensen ON; Siersbæk R
    Nat Genet; 2024 Apr; 56(4):663-674. PubMed ID: 38454021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of tumor oncogenes by disruption of super-enhancers.
    Lovén J; Hoke HA; Lin CY; Lau A; Orlando DA; Vakoc CR; Bradner JE; Lee TI; Young RA
    Cell; 2013 Apr; 153(2):320-34. PubMed ID: 23582323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation.
    Shi J; Whyte WA; Zepeda-Mendoza CJ; Milazzo JP; Shen C; Roe JS; Minder JL; Mercan F; Wang E; Eckersley-Maslin MA; Campbell AE; Kawaoka S; Shareef S; Zhu Z; Kendall J; Muhar M; Haslinger C; Yu M; Roeder RG; Wigler MH; Blobel GA; Zuber J; Spector DL; Young RA; Vakoc CR
    Genes Dev; 2013 Dec; 27(24):2648-62. PubMed ID: 24285714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
    Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
    J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET inhibition disrupts transcription but retains enhancer-promoter contact.
    Crump NT; Ballabio E; Godfrey L; Thorne R; Repapi E; Kerry J; Tapia M; Hua P; Lagerholm C; Filippakopoulos P; Davies JOJ; Milne TA
    Nat Commun; 2021 Jan; 12(1):223. PubMed ID: 33431820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor quiescence: elevating SOX2 in diverse tumor cell types downregulates a broad spectrum of the cell cycle machinery and inhibits tumor growth.
    Metz EP; Wuebben EL; Wilder PJ; Cox JL; Datta K; Coulter D; Rizzino A
    BMC Cancer; 2020 Oct; 20(1):941. PubMed ID: 32998722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
    Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
    Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.
    Tsang FH; Law CT; Tang TC; Cheng CL; Chin DW; Tam WV; Wei L; Wong CC; Ng IO; Wong CM
    Hepatology; 2019 Jun; 69(6):2502-2517. PubMed ID: 30723918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional Dysregulation of MYC Reveals Common Enhancer-Docking Mechanism.
    Schuijers J; Manteiga JC; Weintraub AS; Day DS; Zamudio AV; Hnisz D; Lee TI; Young RA
    Cell Rep; 2018 Apr; 23(2):349-360. PubMed ID: 29641996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
    Gen Y; Muramatsu T; Inoue J; Inazawa J
    Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.